What are FDA’s expectations for establishing acceptable intakes (Als) for potential cohort of concern (CoC) nitrosamines with insufficient safety data?

This and more questions related to Safety on this document recently published by FDA from a recent FDA-Industry meeting AAM/CHPA/PhRMA May 4th

QA Written Responses_Joint Industry Group Meeting on Nitrosamines_final.pdf (133.3 KB)

1 Like